

2.04.123 Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases	
Original Policy Date: October 31, 2014	Effective Date: May 1, 2024
Section: 2.0 Medicine	Page: Page 1 of 23

Policy Statement

- I. Serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic lupus erythematosus and other connective tissue diseases is considered **investigational**.

NOTE: Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Coding
See the [Codes table](#) for details.

Description

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease (CTD) that can be difficult to diagnose because patients often present with diverse, nonspecific symptoms that overlap with other CTDs; to further complicate matters, commonly used laboratory tests are not highly accurate. Moreover, similar symptoms may also present themselves in patients with fibromyalgia. Currently, differential diagnosis depends on a combination of clinical signs and symptoms and individual laboratory tests. More accurate laboratory tests for SLE and other CTDs could facilitate diagnosis of the disease. Recently, laboratory-developed, diagnostic panel tests with proprietary algorithms and/or index scores for the diagnosis of SLE and other autoimmune CTDs have become commercially available.

Related Policies

- N/A

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. The **Avisé**® tests (Exagen Diagnostics) are available under

the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Rationale

Background Connective Tissue Diseases

Systemic Lupus Erythematosus

SLE is an autoimmune CTD. It is one of several types of lupus, the others being cutaneous and drug-induced lupus. About 90% of lupus patients are women between the ages of 15 and 44 years. SLE causes inflammation and can affect any part of the body, most commonly the skin, heart, joints, lungs, blood vessels, liver, kidneys, and nervous system. Although generally not fatal, SLE can increase mortality, most commonly from cardiovascular disease due to accelerated atherosclerosis. SLE can also lead to kidney failure, which may reduce survival. The survival rate in the U. S. is approximately 95% at 5 years and 78% at 20 years.¹ The morbidity associated with SLE is substantial. Symptoms such as joint and muscle pain can impact the quality of life and functional status. SLE also increases patients' risk of infection, cancer, avascular necrosis (bone death), and pregnancy complications (e.g., preeclampsia, preterm birth). The course of the disease is variable, and patients generally experience flares of mild-to-severe illness and remission.

Other Connective Tissue Diseases

Several other CTDs may require a differential diagnosis from SLE (e.g., rheumatoid arthritis, Sjögren syndrome, antiphospholipid syndrome, and polymyositis).

Rheumatoid arthritis is a chronic inflammatory peripheral polyarthritis. Rheumatoid arthritis can lead to deformity through stretching of tendons and ligaments and destruction of joints through erosion of cartilage and bone. Rheumatoid arthritis can also affect the skin, eyes, lungs, heart, and blood vessels.

Graves disease is an autoimmune disorder that leads to overactivity of the thyroid gland. The disease arises from thyroid-stimulating hormone receptor antibodies. It is the most common cause of hyperthyroidism. Blood tests may show raised thyroid-stimulating immunoglobulin antibodies.

Hashimoto disease, also known as chronic lymphocytic thyroiditis, is an autoimmune disorder and is the most common cause of hypothyroidism second to iodine insufficiency. It is characterized by an underactive thyroid gland and gradual thyroid failure. Diagnosis is confirmed with blood tests for thyroid-stimulating hormone (T4) and antithyroid antibodies.

Sjögren syndrome is an autoimmune disorder characterized by dryness of the eyes and mouth due to diminished lacrimal and salivary gland function. Affected individuals may also have symptoms of fatigue, myalgia, and cognitive dysfunction, which may be difficult to distinguish clinically from fibromyalgia or medication side effects. Typical antibodies include antinuclear antibody (ANA), anti-Sjögren-syndrome-related antigen, anti-Sjögren syndrome type B, or rheumatoid factor.

Antiphospholipid syndrome is a systemic autoimmune disorder characterized by venous or arterial thrombosis and/or pregnancy morbidity. Antiphospholipid antibodies are directed against phospholipid-binding proteins.

Polymyositis and dermatomyositis are inflammatory myopathies characterized by muscle weakness and inflammation. Dermatomyositis may also have skin manifestations.

Diagnosis

Patients with SLE often present with nonspecific symptoms such as fever, fatigue, joint pain, and rash, which can make the disease difficult to diagnose. In some patients, the diagnosis of SLE can be made with certainty (e.g., when there are typical symptoms of rash and joint symptoms, and laboratory testing shows a high-titer abnormal ANA in a pattern specific for SLE). However, in many other patients, the symptom patterns of SLE are less clear, and ANA testing is equivocal; as a result, cascade testing with additional serologic tests may be ordered. In addition, ANA testing alone can result in false-positives due to low specificity.

Classifications

The diagnosis of SLE has been based on a combination of clinical symptoms and laboratory results. In 1997 the American College of Rheumatology (ACR) updated 1982 criteria for the classification of SLE.^{2,3}

The ACR classification criteria are as follows:

- 1.Malar rash
- 2.Discoïd rash
- 3.Photosensitivity
- 4.Mouth or nose ulcers (usually painless)
- 5.Arthritis (nonerosive) in two or more peripheral joints, along with tenderness, swelling, or effusion
- 6.Serositis: pleuritis or pericarditis
- 7.Renal disorder: excessive protein in the urine, or cellular casts in the urine
- 8.Neurologic disorder: seizures and/or psychosis, in the absence of offending drugs or known metabolic derangements
- 9.Hematologic disorders: hemolytic anemia, leukopenia, lymphopenia, or thrombocytopenia
- 10.Immunologic disorder: antibodies to double-stranded DNA (anti-dsDNA), antibodies to Smith antigen (anti-Sm), positive antiphospholipid antibody, or false-positive serologic test for syphilis known to be positive for at least six months
- 11.ANA test in the absence of drugs known to induce it.

These criteria were originally developed for research but they have been widely adopted in clinical care. Individuals who meet 4 or more of the 11 criteria are diagnosed with SLE. If a patient meets fewer than four of the criteria, lupus can still be diagnosed by clinical judgment; it is recommended that a rheumatologist confirm the diagnosis.⁴ ANA testing is usually performed for patients who present with signs and symptoms involving two or more organ systems, and individuals who test positive are recommended for additional laboratory testing.⁵ Assessments of ACRs 1982 criteria have reported sensitivities ranging from 78% to 95% and specificities ranging from 89% to 100%, with lower accuracy in patients with mild disease.⁵

The Systemic Lupus International Collaborating Clinics (SLICC; 2012), an international research group, developed revised criteria for diagnosing SLE.⁶ These criteria include more laboratory tests than the earlier ACR criteria, including elements of the complement system. Patients are classified as having SLE if they satisfy 4 or more of the 18 criteria below, including at least 1 clinical criterion and 1 immunologic criterion, or they have biopsy-confirmed nephritis compatible with SLE and with ANA or anti-dsDNA antibodies. In a sample of 690 patients, the SLICC criteria had a sensitivity of 97% and a specificity of 84% for diagnosing SLE, whereas the ACR criteria applied to the same sample had a sensitivity of 83% and a specificity of 96%. It is not clear how well-accepted the SLICC recommendations are in the practice setting. Table 1 outlines the SLICC criteria.

Table 1. Clinical and Immunologic Criteria

Clinical Criteria
•Acute cutaneous lupus (including but not limited to lupus malar rash)
•Chronic cutaneous lupus (including but not limited to discoïd rash)

Clinical Criteria

- Oral ulcers
- Nonscarring alopecia in the absence of other causes
- Synovitis involving ≥ 2 joints, characterized by swelling or effusion or and ≥ 30 min of morning stiffness
- Serositis
- Renal: excessive protein in the urine or cellular casts in the urine
- Neurologic disorder: seizures, psychosis, mononeuritis complex, or peripheral, or cranial neuropathy
- Seizures
- Hemolytic anemia
- Leukopenia or lymphopenia
- Thrombocytopenia

Immunologic Criteria

- Antinuclear antibody above laboratory reference range
 - Antibodies to double-stranded DNA above laboratory reference range
 - Antibodies to Smith nuclear antigen
 - Antiphospholipid antibody
 - Low complement (low C3, low C4, or low CH50)
 - Direct Coombs tests in the absence of hemolytic anemia
-

As noted, the SLICC classification system includes a wider range of laboratory tests than the ACR criteria. To date, the most common laboratory tests performed in the diagnosis of SLE are serum ANA, and, if positive, tests for anti-dsDNA and anti-Sm. ANA tests are highly sensitive (i.e., with a high negative predictive value) but have low specificity and relatively low positive predictive value, particularly when the ANA is positive at a low level. Specificity of testing can be increased by testing for specific antibodies against individual nuclear antigens (extractable nuclear antigens) to examine the "pattern" of ANA positivity. These include antigens against single- and dsDNA, histones, Sm, Ro, La, and RNP antibodies. The presence of anti-dsDNA or anti-Sm is highly specific for SLE because few patients without SLE test positive; however, neither test has high sensitivity.⁷ The presence of other antibody patterns may indicate the likelihood of other diagnoses. For example, the presence of Ro and La antibodies suggests Sjögren syndrome, while the presence of antihistone antibodies suggests drug-induced lupus.

Better diagnostic tests for SLE and other CTDs would be useful in clinical practice. A variety of biomarkers, including markers associated with the complement system, are being explored to aid in the diagnosis of lupus. The complement system is part of the immune system and consists of 20 to 30 protein molecules that circulate in the blood in an inactive form until activated by a trigger (e.g., an infection), and when the protein molecules are activated, a sequence of events known as the complement cascade is initiated. This cascade involves the proteolysis of a complement protein into a smaller protein and a peptide. The smaller protein is able to bind to the complex one at the surface of the invading microorganism, and the peptide diffuses away. For example, in the first step, complement protein C3 is cleaved into C3b and C3a. C3b binds to the surface of the microorganism and activates the next step in the cascade, the proteolysis of C5, and the small peptide, C3a diffuses away. The precursors C3 and C4 and the complement activation products (e.g., C3a, C5a, C4d) have been considered as SLE biomarkers. More recently, cell-bound complement activation products, which live longer than circulating complement activation products, have been investigated as biomarkers of SLE.

In addition to the exploration of individual biomarkers with higher accuracy than accepted markers (e.g., ANA, anti-dsDNA), there is interest in identifying a panel of tests with high sensitivity and specificity for SLE diagnosis. At least one multibiomarker test to aid diagnosis of SLE and other CTDs is commercially available. This panel, Avise CTD (Exagen Diagnostics), contains 22 different tests. It combines 2 smaller panels, a 10-marker panel that includes common SLE tests, as well as cell-bound complement activation products (known as Avise Lupus) and a 12-marker panel that focuses on CTDs other than SLE (known as Avise CTD). Avise CTD includes nuclear antigen antibodies markers to help distinguish CTD, a rheumatoid arthritis panel to rule-in or rule-out rheumatoid arthritis, an antiphospholipid syndrome panel to assess risk for thrombosis and cardiovascular events, and a

thyroid panel to help rule-in or rule-out Graves disease and Hashimoto disease. Specific biomarkers in the panel are listed in Table 2.

Table 2. Avise Systemic Lupus Erythematosus Tests

Systemic Lupus Erythematosus Tests
10-marker Avise Lupus test
Auto-antibodies: ANA, anti-dsDNA, antimutated citrullinated vimentin, C4d erythrocyte-bound complement fragment, C4d lymphocyte-bound complement, anti-Sm, Jo-1, Sci-70, CENP, SS-B/La
Avise CTD test
Avise Lupus test plus the following:
Auto-antibodies: UIRNP, RNP70, SS-A/Ro
Rheumatoid arthritis auto-antibodies: rheumatoid factor IgM, rheumatoid factor IgA, anti-cyclic citrullinated peptide IgG
Anti-phospholipid syndrome auto-antibodies: cardiolipin IgM, cardiolipin IgG, β2-glycoprotein 1 IgG, β2-glycoprotein 1 IgM
Thyroid auto-antibodies: thyroglobulin IgG, thyroid, thyroid peroxidase

ANA: antinuclear antibody; anti-dsDNA: antibodies to double-stranded DNA; anti-Sm: antibodies to Smith nuclear antigen; CTD: connective tissue disease; Ig: immunoglobulin.

The Avise CTD test assesses all 22 markers. Avise CTD uses a three-step process.⁸ The 10-marker panel is done in 2 tiers, and the add-on 12-marker panel is done in a third step to further assist with the differential diagnosis of CTD. In addition, ANA testing is done by enzyme-linked immunosorbent assay and by indirect immunofluorescence. The 2-tiered testing approach to the 10-marker panel is described next.

Tier 1: Tests for anti-Sm, EC4d, BC4d, and anti-dsDNA. If any tests are positive, the result is considered suggestive of SLE and no further testing is done. Cutoffs for positivity are greater than 10 U/mL for anti-Sm, greater than 75 U/mL for EC4d, greater than 200 U/mL for BC4d, and greater than 301 U/mL for anti-dsDNA. Positive findings for anti-dsDNA are confirmed with a *Crithidialuciliae* assay.

Tier 2: If the tier 1 tests are negative, an index score is created, consisting of results of tests for ANA, EC4d and BC4d, antimutated citrullinated vimentin, anti-Jo-1, anti-Sci-70, anti-CENP, and anti-Ss-B/La. In other words, there are six additional markers and the ratio of EC4d to BC4d, both of which were measured in tier 1.

The index score (tier 2), calculated using a proprietary algorithm, rates how suggestive test results are of SLE. Although there is information on cutoffs used to indicate positivity for individual markers, information is not available on how precisely the index score is calculated. The score can range from -5 (highly nonsuggestive of SLE) to 5 (highly suggestive of SLE), and a score of -0.1 to 0.1 is considered indeterminate.

Exagen also offers the Avise Lupus Prognostic test, a 10-marker panel that can be ordered with the Avise Lupus and Avise CTD panels. The prognostic test focuses on patients' risk of lupus nephritis, neuropsychiatric SLE, thrombosis, and cardiovascular events. The test includes anti-Clq, anti-ribosomal P, anti-phosphatidylserine/prothrombin immunoglobulin (Ig) M and IgG, anti-cardiolipin IgM, IgG, and IgA and anti- β 2-glycoprotein 1 IgM, IgG, and IgA. Four of the ten markers are included in both panel tests.

Treatment

Treatments for SLE can ameliorate symptoms, reduce disease activity, and slow progression of organ damage; however, there is no cure. Muscle and joint pain, fatigue, and rashes are generally treated initially with nonsteroidal anti-inflammatory drugs. Antimaltimes drugs such as hydroxychloroquine can relieve some symptoms of SLE including fatigue, rashes, and joint pain. Patients with more severe symptoms (e.g., heart, lung, or kidney involvement) can be treated with corticosteroids or

immune suppressants. There are also biologic treatments (e.g., rituximab) approved by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis and are being evaluated for SLE.

Literature Review

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

Systemic Lupus Erythematosus

Clinical Context and Test Purpose

The purpose of serum biomarker panel testing is to provide an option that is an alternative to or an improvement on existing tests for diagnosis and management, such as established systemic lupus erythematosus (SLE) classification systems and individual serum biomarker tests, in individuals with signs and/or symptoms of SLE.

The following PICO was used to select literature to inform this review.

Populations

The population of interest is individuals with signs and/or symptoms of SLE. Individuals with SLE often present with nonspecific symptoms such as fever, fatigue, joint pain, and rash, which can make the disease difficult to diagnose. In some individuals, the diagnosis of SLE can be made with certainty (e.g., when there are typical rash and joint symptoms, and laboratory testing shows a high-titer abnormal antinuclear antibody [ANA] in a pattern specific for SLE). However, in many other individuals, the symptom patterns of SLE are less clear, and ANA testing is equivocal; as a result, cascade testing with additional serologic tests may be ordered. In addition, ANA testing alone can result in false-positives due to low specificity.

Interventions

The test being considered is serum biomarker panel testing. Systemic lupus erythematosus is an autoimmune connective tissue disease (CTD) that can be difficult to diagnose because individuals often present with diverse, nonspecific symptoms that overlap with other CTDs; to further complicate matters, commonly used laboratory tests are not highly accurate. Moreover, similar symptoms may also present themselves in individuals with fibromyalgia. Currently, differential diagnosis depends on a combination of clinical signs and symptoms and individual laboratory tests. More accurate laboratory tests for SLE and other CTDs could facilitate the diagnosis of the disease. Recently, laboratory-developed, diagnostic panel tests with proprietary algorithms and/or index scores for the diagnosis of SLE and other autoimmune CTDs have become commercially available.

At least 1 multibiomarker test to aid diagnosis of SLE and other CTDs is commercially available. This panel, Avise CTD (Exagen Diagnostics), contains 22 different tests. It combines 2 smaller panels, a 10-marker panel that includes common SLE tests, as well as cell-bound complement activation products (known as Avise Lupus) and a 12-marker panel that focuses on CTDs other than SLE (known as Avise CTD). Avise CTD includes nuclear antigen antibody markers to help distinguish CTD, a rheumatoid arthritis panel to rule-in or rule-out rheumatoid arthritis, an antiphospholipid syndrome panel to assess risk for thrombosis and cardiovascular events, and a thyroid panel to help rule-in or rule-out Graves disease and Hashimoto's disease. Specific biomarkers in the panel are listed in Table 1.

Table 1. Avise Systemic Lupus Erythematosus Tests

Systemic Lupus Erythematosus Tests
10-marker Avise Lupus test
Auto-antibodies: ANA, anti-dsDNA, antimutated citrullinated vimentin, C4d erythrocyte-bound complement fragment, C4d lymphocyte-bound complement, anti-Sm, Jo-1, Sci-70, CENP, SS-B/La
Avise CTD test
Avise Lupus test plus the following:
Auto-antibodies: U1RNP, RNP70, SS-A/Ro
Rheumatoid arthritis auto-antibodies: rheumatoid factor IgM, rheumatoid factor IgA, anti-cyclic citrullinated peptide IgG
Anti-phospholipid syndrome auto-antibodies: cardiolipin IgM, cardiolipin IgG, β2-glycoprotein 1 IgG, β2-glycoprotein 1 IgM
Thyroid auto-antibodies: thyroglobulin IgG, thyroid, thyroid peroxidase

ANA: antinuclear antibody; anti-dsDNA: antibodies to double-stranded DNA; anti-Sm: antibodies to Smith nuclear antigen; CENP: centromere protein; CTD: connective tissue disease; Ig: immunoglobulin; RNP: ribonucleoprotein.

The Avise CTD test assesses all 22 markers. Avise CTD uses a 3 step process.² The 10-marker panel is done in 2 tiers, and the add-on 12-marker panel is done in a third step to further assist with the differential diagnosis of CTD. In addition, ANA testing is done by enzyme-linked immunosorbent assay and by indirect immunofluorescence. The 2-tiered testing approach to the 10-marker panel is described next.

Tier 1: Tests for antibodies to Smith nucleaer antigen (anti-Sm), erythrocyte-bound C4d (EC4d), B-cell-bound C4d (BC4d), and antibodies to double-stranded DNA (anti-dsDNA). If any tests are positive, the result is considered suggestive of SLE and no further testing is done. Cutoffs for positivity are greater than 10 U/mL for anti-Sm, greater than 75 U/mL for EC4d, greater than 200 U/mL for BC4d, and greater than 301 U/mL for anti-dsDNA. Positive findings for anti-dsDNA are confirmed with a *Crithidia lucilliae* assay.

Tier 2: If the tier 1 tests are negative, an index score is created, consisting of results of tests for ANA, EC4d and BC4d, anti-mutated citrullinated vimentin, anti-histidyl transfer RNA synthetase (anti-Jo-1), anti-topoisomerase I (anti-Scl-70), anti-centromere protein (anti-CENP), and anti-Sjögren Syndrome-B (anti-SSB/La) antibody tests. In other words, there are 6 additional markers and the ratio of EC4d to BC4d, both of which were measured in tier 1.

The index score (tier 2), calculated using a proprietary algorithm, rates how suggestive test results are of SLE. Although there is information on cutoffs used to indicate positivity for individual markers, information is not available on how precisely the index score is calculated. The score can range from -5 (highly nonsuggestive of SLE) to 5 (highly suggestive of SLE), and a score of -0.1 to 0.1 is considered indeterminate.

Exagen also offers the Avise Lupus Prognostic test, a 10-marker panel that can be ordered with the Avise Lupus and Avise CTD panels. The prognostic test focuses on patients' risk of lupus nephritis, neuropsychiatric SLE, thrombosis, and cardiovascular events. The test includes anti-C1q, anti-ribosomal P, anti-phosphatidylserine/prothrombin immunoglobulin (Ig) M and IgG, anti-cardiolipin

IgM, IgG, and IgA and anti- β 2-glycoprotein 1 IgM, IgG, and IgA. Four of the 10 markers are included in both panel tests.

Additionally, in 2017, Exagen released an advanced blood test that incorporates specialized lupus biomarkers to assist in evaluating SLE disease activity - the AVISE SLE Monitor. The AVISE SLE Monitor test includes EC4d, a patented lupus biomarker that measures complement activation, a novel testing method to better assess changes in anti-dsDNA levels, PC4d (a patented lupus biomarker significantly associated with a history of thrombosis), and the anti-C1q biomarker that assists in evaluating lupus activity and possible kidney damage. C3 and C4 testing is also incorporated in the AVISE SLE Monitor; low levels of these proteins may indicate increased lupus disease activity.

Comparators

Comparators of interest include established SLE classification systems (e.g., American College of Rheumatology [ACR], Systemic Lupus International Collaborating Clinics [SLICC]) and clinical diagnosis based on clinical and laboratory findings, such as individual serum biomarker tests, with exclusion of alternative diagnoses.

The diagnosis of SLE has been based on a combination of clinical symptoms and laboratory results. Previously, the ACR published a 1982 criteria for classifying SLE. In 1997, the ACR updated the 1982 criteria for the classification of SLE.^{3,4} In 2019, new classification criteria endorsed by the European League Against Rheumatism (EULAR) and the ACR were developed and validated.⁵ The 2019 EULAR/ACR classification criteria requires a positive ANA as an entry criterion. For those with a positive ANA, additive criteria are assessed in 7 clinical and 3 immunological domains. Weighted criteria (ranging from 2 to 10 points) are evaluated within each domain, with only the highest weighted criterion in a specific domain counting towards the total score. The weighted feature allows for criteria that are more tightly associated with SLE to contribute more heavily to the overall score. A classification of SLE requires a total score of ≥ 10 points.

The EULAR/ACR classification criteria are as follows:

- Entry criterion: ANA at a titer of $\geq 1:80$ on HEp-2 cells or an equivalent positive test
- If entry criterion is present, apply additive criteria (weight):
 - Constitutional: fever (2)
 - Hematologic: leukopenia (2), thrombocytopenia (4), autoimmune hemolysis (4)
 - Neuropsychiatric: delirium (2), psychosis (3), seizure (5)
 - Mucocutaneous: non-scarring alopecia (2), oral ulcers (2), subacute cutaneous or discoid lupus (4), acute cutaneous lupus (6)
 - Serosal: pleural or pericardial effusion (5), acute pericarditis (6)
 - Musculoskeletal: joint involvement (6)
 - Renal: proteinuria >0.5 g/24 h (4), renal biopsy Class II or V lupus nephritis (8), renal biopsy Class III or IV lupus nephritis (10)
 - Antiphospholipid antibodies: anti-cardiolipin antibodies or anti- β 2GPI antibodies or lupus anticoagulant (2)
 - Complement proteins: low C3 or low C4 (3), low C3 and low C4 (4)
 - SLE-specific antibodies: anti-dsDNA or anti-Sm (6)

The ACR criteria were originally developed for research but they have been widely adopted in clinical care. If a patient does not fulfill criteria for classification for SLE, lupus can still be diagnosed by clinical judgment; it is recommended that a rheumatologist confirm the diagnosis.⁶ Validation of the 2019 EULAR/ACR criteria reported a sensitivity of 96.1% and a specificity of 93.4%.⁵ In comparison, the validation cohort for the ACR 1997 updated criteria reported 82.8% sensitivity and 93.4% specificity. Lastly, it should be noted that the development of the 2019 EULAR/ACR criteria aimed to improve the detection of early or new onset SLE compared to older ACR criteria.

Additionally, the SLICC, an international research group, developed revised criteria for diagnosing SLE in 2012.⁷ These criteria include more laboratory tests than the 1997 ACR criteria, including elements of the complement system. Patients are classified as having SLE if they satisfy 4 or more of the 18 criteria below, including at least 1 clinical criterion and 1 immunologic criterion, or they have biopsy-confirmed nephritis compatible with SLE and with ANA or anti-dsDNA antibodies. In a sample of 690 patients, the SLICC criteria had a sensitivity of 97% and a specificity of 84% for diagnosing SLE, whereas the ACR criteria applied to the same sample had a sensitivity of 83% and a specificity of 96%. It is not clear how well-accepted the SLICC recommendations are in the practice setting. Table 2 outlines the SLICC criteria.

Table 2. Clinical and Immunologic Criteria

Clinical Criteria	
Acute cutaneous lupus (including but not limited to lupus malar rash)	
Chronic cutaneous lupus (including but not limited to discoid rash)	
Oral ulcers	
Nonscarring alopecia in the absence of other causes	
Synovitis involving ≥ 2 joints, characterized by swelling or effusion or and ≥ 30 min of morning stiffness	
Serositis	
Renal: excessive protein in the urine or cellular casts in the urine	
Neurologic disorder: seizures, psychosis, mononeuritis complex, or peripheral, or cranial neuropathy	
Seizures	
Hemolytic anemia	
Leukopenia or lymphopenia	
Thrombocytopenia	
Immunologic Criteria	
Antinuclear antibody above laboratory reference range	
Antibodies to double-stranded DNA above laboratory reference range	
Antibodies to Smith nuclear antigen	
Antiphospholipid antibody	
Low complement (low C3, low C4, or low CH50)	
Direct Coombs tests in the absence of hemolytic anemia	

To date, the most common laboratory tests performed in the diagnosis of SLE are serum ANA, and, if positive, tests for anti-dsDNA and anti-Sm. Antinuclear antibody tests are highly sensitive (ie, with a high negative predictive value) but have low specificity and relatively low positive predictive value, particularly when the ANA is positive at a low level. Specificity of testing can be increased by testing for specific antibodies against individual nuclear antigens (extractable nuclear antigens) to examine the "pattern" of ANA positivity. These include antigens against single- and dsDNA, histones, Sm, Ro, La, and ribonucleoprotein (RNP) antibodies. The presence of anti-dsDNA or anti-Sm is highly specific for SLE because few patients without SLE test positive; however, neither test has high sensitivity.⁸ The presence of other antibody patterns may indicate the likelihood of other diagnoses. For example, the presence of Ro and La antibodies suggests Sjögren syndrome, while the presence of antihistone antibodies suggests drug-induced lupus.

Outcomes

General outcomes of interest are test accuracy, symptoms, and quality of life, as described in Table 3.

Table 3. Outcomes of Interest for Individuals With Signs and/or Symptoms of Systemic Lupus Erythematosus

Outcomes	Details
Test accuracy	Sensitivity and specificity in detecting biomarkers for SLE [FU for several years to assess accuracy of diagnosis]
Symptoms	Malar rash, discoid rash, photosensitivity, mouth or nose ulcers, arthritis (nonerosive), among others [≥ 2 weeks]
Quality of life	Relief of symptoms [≥ 3 years] Reduction in joint and organ damage [≥ 3 years]

FU: follow-up; SLE: systemic lupus erythematosus.

More specifically, outcomes of interest for SLE include disease activity indices, organ damage, reduction in flares, and reduction in concomitant corticosteroids.⁹ Patient reported outcomes are also encouraged, particularly ones that measure fatigue as most experts agree that it is one of the most important symptoms of SLE. However, the U.S. Food and Drug Administration (FDA) has not identified an existing instrument optimal for measuring fatigue in patients with SLE. Both fatigue and pain are the most consequential and frequent symptoms in SLE and these contribute significantly to physical functioning, sleep, and the ability to complete daily tasks, among other quality of life measures.¹⁰ Validated instruments for measuring quality of life in SLE are mainly used in clinical trials. Systemic lupus erythematosus specific measures include the Lupus-quality-of-life and SLE-specific quality-of-life (SLEQOL) instruments; additionally general quality of life measures are also used to measure health-related quality of life (e.g., Short Form 36 [SF-36]). Recommended health outcome measures for disease activity and organ damage per FDA guidance is summarized in Table 4.^{9,11}

Table 4. Health Outcome Measures Relevant to Systemic Lupus Erythematosus

Outcome	Measure (Units)	Assessment	Description	Clinical Interpretation (if available)
Disease activity index BILAG 2004¹²	Disease activity is scored from A to E	Disease activity within last month	Ordinal scale index that assesses 9 individual organ systems. Disease activity is scored and converted into 5 levels from A to E. Grade A is very active disease requiring anticoagulation therapy, while Grade E is no current or previous disease activity.	Major clinical response as defined by the FDA as BILAG C scores or better at 6 months with no new BILAG A or B scores with maintenance of response between 6 to 12 months.
SLEDAI-2K¹³	Scale from 0 to 105	Disease activity within last 10 days	A 24-item assessment of 16 clinical symptoms and 8 laboratory results that covers 9 organ systems. Items are weighted giving individual item scores ranging from 1 to 8. Categories of activity range from inactive (score of 0) to very active (score >12).	A score of 6 is considered clinically important and affects the decision to treat.
SLAM-R¹⁴	Scale from 0 to 81	Disease activity within last month	Evaluates 9 organ systems plus 7 laboratory features. Each organ item is scored 0 to 3 points. Laboratory categories can score a maximum of 21 points. Higher scores indicate higher disease activity.	A score of 7 is considered clinically important and affects the decision to treat.
ECLAM¹⁵	Scale from 0 to 17.5	Disease activity within last month	A 33-item assessment that is organized into 12 categories, including 10 organ symptoms plus ESR and complement levels. Individual item scores range from 0.5 to 2. Higher scores indicate higher disease activity.	-

Outcome	Measure (Units)	Assessment	Description	Clinical Interpretation (if available)
Organ damage assessment				
SLICC/ACR damage index ¹⁶	Scale from 0 to 46	Disease damage present for ≥ 6 months or after irreversible event	Captures items of permanent change after a diagnosis of SLE that covers specific manifestations in 12 organ systems. The 41-item assessment scores the presence of organ damage from 1 to 3 points. Higher scores indicate higher damage.	Organ damage is considered if the score is ≥ 1 . Cumulative damage is a poor prognostic sign and a predictor of mortality.

ACR: American College of Rheumatology; BILAG: British Isles Lupus Assessment Group; ECLAM: European Consensus Lupus Activity Measure; ESR: erythrocyte sedimentation rate; FDA: U.S. Food and Drug Administration; SLAM-R: Systemic Lupus Erythematosus Activity Measure revised; SLE: systemic lupus erythematosus; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC: Systemic Lupus Erythematosus International Collaborating Clinics.

Lastly, a quicker diagnosis of SLE could allow the initiation of treatments for SLE sooner. Treatments for SLE can ameliorate symptoms, reduce disease activity, and slow progression of organ damage; however, there is no cure. Muscle and joint pain, fatigue, and rashes are generally treated initially with nonsteroidal anti-inflammatory drugs. Anti-malarial drugs such as hydroxychloroquine can relieve some symptoms of SLE including fatigue, rashes, and joint pain. Patients with more severe symptoms (e.g., heart, lung, or kidney involvement) can be treated with corticosteroids or immune suppressants. There are also biologic treatments (e.g., rituximab) approved by the FDA for the treatment of rheumatoid arthritis and are being evaluated for SLE.

Study Selection Criteria

Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operating characteristic [ROC], area under receiver operating characteristic [AUROC], c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of diagnostic or risk category.
- Studies involving panel testing should report on commercially-marketed tests.

Several studies were excluded from the evaluation of the clinical validity of serum biomarker panel testing because they did not use the marketed version of the test¹⁷, or only evaluated the cell-bound complement activation products (CB-CAPs) component of commercially available multianalyte tests^{18,19}.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

Retrospective Studies

Putterman et al (2014) published data from a large cross-sectional, industry-sponsored study evaluating serum biomarkers for the diagnosis of SLE.²⁰ They analyzed the 10 markers in the Avise Lupus test (plus ANA) using a 2-tier testing logic similar to that employed in the commercially available panel. The study evaluated 2 cohorts (N=794); 593 participants were enrolled between April and August 2010, and 201 participants enrolled between June 2011 and September 2013. Together, the 2 cohorts consisted of 304 patients who met ACR classification criteria for SLE, 161 patients diagnosed with other rheumatic diseases, and 205 healthy volunteers. Results of serum testing were available for 764 (96%) of 794 participants. A total of 140 (46%) patients with SLE, 9 (3%) patients with other diseases, and 1 healthy volunteer tested positive for at least 1 of the 4 tier 1 markers. Patients testing negative for tier 1 tests underwent tier 2 testing and an index score was calculated. A total of 102 (62%) of 164 patients with SLE analyzed in tier 2 had an index score greater than 0 (ie, suggestive of SLE). Moreover, 245 of 276 patients with other rheumatic diseases had an index score of less than 0 (ie, not suggestive of SLE). When the results of tier 1 and 2 tests were combined, the overall sensitivity for SLE was 80% (242/304) and the overall specificity for distinguishing SLE from other diseases was 86% (245/285). The specificity for distinguishing between SLE and healthy volunteers was 98% (201/205). A limitation of Putterman et al (2014) is that the study sample population included patients with SLE who met ACR classification criteria, but not patients with symptoms suggestive of SLE who failed to meet ACR criteria. It is not known how the diagnostic accuracy of the panel test compares with the ACR classification criteria or with concurrent clinician diagnosis (the mean time since SLE diagnosis was 11 years).

Wallace et al (2016) analyzed serum biomarkers as well as an algorithm for diagnosing SLE.²¹ This study analyzed markers in the Avise Lupus (plus ANA) test using a 2-tier testing logic to evaluate SLE patients who met ACR criteria (n=75) and patients with primary fibromyalgia (n=75). Use of a multianalyte assay with the algorithm, including CB-CAP levels, generated indeterminate results in 12 of the 150 subjects enrolled. For the remainder of patients, use of the algorithm to diagnosis SLE was 60% sensitive and 100% specific. Study limitations included a selection of patients with a well-established diagnosis and long duration of disease.

Mossell et al (2016) reported on an industry-sponsored retrospective case-control study of 23 patients who had a positive Avise Lupus test result and 23 patients who had a negative result.²² All patients were ANA-positive but negative for auto-antibodies specific for SLE, representing cases difficult to diagnose. Each positive Avise test case was matched to a control (negative test) from the same clinic with the same ANA level. A chart review was performed by a nonblinded rheumatologist approximately 1 year after the test results were available. Of the cases with a positive Avise Lupus test, 20 (87%) were diagnosed with SLE during follow-up. This compared with 4 (17%) individuals who had a negative result on the Avise Lupus test, resulting in a sensitivity of 83.3% and specificity of 86.4%. Interpretation of this study is limited due to its retrospective design, relatively short follow-up to monitor the progression of the disease, and the lack of an independent reference standard, because the diagnosis was based in part on the results of that test.

Liang et al (2020) conducted a retrospective single-center study of 117 patients in a rheumatology clinic without a confirmed SLE diagnosis who had received an Avise CTD test as part of their clinical care between April 2014 and November 2016.²³ The study aimed to determine whether the Avise test would aid in assessing the risk of developing SLE in patients who had undifferentiated findings presenting in a real-world setting. At the clinic, patients who had inflammatory arthritis, undifferentiated CTD, or other diagnoses or features suggestive of SLE received Avise testing. In this cohort of patients without a diagnosis of SLE at baseline, the diagnosis at 2 years from baseline changed in 80% (16/20) of patients who had a positive test as opposed to only 28.9% (28/97) who had a non-positive test. Of the 20 patients who had a positive test, 13 (65%) had their diagnosis changed to SLE at 2 years. The Avise test was associated with a specificity of 93%, with a sensitivity of 57%, positive predictive value of 65%, and negative predictive value of 90%. The study also

observed that patients with a positive Avise test had a significant accrual of clinical features, as defined by SLICC and ACR criteria, as well as organ damage, as defined by the SLICC Damage Index, compared to those without a positive test over the 2 year period. Additionally, there were no significant differences in medication regimens received by positive versus non-positive patients at baseline or at 2 years, except for more frequent use of mycophenolate mofetil in positive patients at year 2. Limitations of the study include its retrospective design and the potential for confirmation bias as treating physicians were aware of the Avise results and were potentially less likely to diagnose SLE in a patient with a negative Avise test.

O'Malley et al (2022) reported results of the CAPSTONE retrospective study (N=44,605) of electronic health record data from 2016 to 2020 from 300 US rheumatologists.²⁴ The study compared the likelihood of SLE diagnosis and SLE treatment initiation between AVISE testing and an ANA testing strategy. The testing results from the AVISE test were obtained directly from the laboratory vendor. The test results for the ANA tests were obtained from the electronic health record by searching for all variants of ANA and related test names. The study participants had a mean age in the early- to mid-50s, were mostly female (>80%), and mostly White (>55%). AVISE positive patients were more likely to initiate SLE medications compared with ANA positive patients (adjusted odds ratio [OR], 2.1; 95% confidence interval [CI], 1.9 to 2.4). AVISE positive patients were more likely to be diagnosed with SLE, as compared with the ANA patients (31% vs 8%; adjusted OR, 4.8; 95% CI, 4.0 to 5.7). The study is limited by its retrospective, non-paired design. The ANA comparator is only a subset of the standard diagnostic information used in practice.

Prospective Studies

Ramsey-Goldman et al (2020) evaluated a multianalyte assay panel (MAP) in patients with suspected SLE to predict progression to SLE as classified by ACR criteria in an industry-sponsored prospective observational study at 7 academic institutions.²⁵ Patients with probable SLE as suspected by lupus experts who also met 3 ACR criteria (n=92) were enrolled along with patients with established SLE based on ACR and SLICC criteria (n=53). A control group of patients with primary Sjögren's syndrome and other rheumatic diseases (n=101) were also included. The multianalyte panel with algorithm evaluated was the Avise Lupus test. The sensitivity of MAP at enrollment was higher compared to anti-dsDNA levels or low complement levels. The ability of positive MAPs to predict fulfillment of the ACR criteria at 9 to 18 months after enrollment was also analyzed. In the subgroup of 20 patients with probable SLE who fulfilled ACR criteria within 18 months, 8 (40%) had a MAP score >0.8 at enrollment. Kaplan-Meier estimates found that a MAP score >0.8 was predictive of progression to classifiable SLE (hazard ratio, 3.11 ; 95% CI, 1.26 to 7.69). A limitation of the study was the relatively small population of patients with probable SLE. Ramsey-Goldman et al (2021) continued to follow patients with probable SLE from their original report to better determine whether more patients transitioned to classifiable SLE and whether the MAP score retained its ability to predict this transition.²⁶ Of the 92 patients with probable SLE, 74 had 1 or 2 follow-up visits 9 to 35 months after enrollment (total follow-up visits: 128). Twenty-eight patients with probable SLE (30.4%) were found to transition to ACR-classifiable SLE. This included 16 individuals in the first year and 12 afterwards. A MAP score >0.8 at enrollment continued to predict a transition to classifiable SLE during follow-up (hazard ratio, 2.72; p=.012); individual biomarkers or fulfillment of SLICC criteria did not.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

Randomized Controlled Trials

Serum biomarker panel tests should be compared with usual clinical diagnosis assessments. Clinical diagnosis for SLE is not standardized, but generally consists of assessments of individual biomarkers in patients with signs and symptoms suspicious of SLE. One RCT is available directly comparing serum biomarker panel tests to standard diagnosis laboratory testing.²⁷ Characteristics of the trial are shown in Table 5.

Table 5. Summary of Randomized Controlled Trial Characteristics

Trial	Countries	Sites	Dates	Participants	Interventions
Wallace et al (2019); CARE for Lupus trial²⁷	United States	32	July 2017 to December 2018	145 patients who were referred to a rheumatologist with a clinical suspicion for SLE, including a history of ANA positivity	Active Comparator Avisé Lupus test (n=72) Standard diagnosis laboratory testing (n=73)
				Participant demographics:	
				<ul style="list-style-type: none"> • Gender: ~94% female • Race: ~70% White, ~21% Black, ~2.7% Asian, ~5.6% Other 	

ANA: antinuclear antibody; CARE: Clinical Laboratory Assessment and Recommendations for Lupus; SLE: systemic lupus erythematosus.

Health outcome results for RCTs are summarized in Table 6. Wallace et al (2019) reported quality of life measures with the 5-level EuroQOL-5 Dimension index ; however, outcomes were not reported by treatment group.

Table 6. Summary of Randomized Controlled Trial Results

	Disease activity	Initiation of SLE-specific treatment	Quality of life
Wallace et al (2019)²⁷	<i>Change in PGA from baseline to week 12</i>	<i>Initiation of hydroxychloroquine</i>	<i>Change from baseline to week 12 for EQ5D-5L</i>
N	145	145	145
Avisé Lupus test	-0.39 ± 0.08	25%	Not reported by treatment group
Standard diagnosis laboratory testing	-0.29 ± 0.06	14%	
Difference (95% CI)	Not reported (p=.39)	Not reported (p=.14)	

CI: confidence interval; EQ5D-5L: 5-level EuroQOL-5 Dimension; PGA: physician global assessment; SLE: systemic lupus erythematosus.

Wallace et al (2019) evaluated the clinical utility of the Avisé Lupus test for the diagnosis of lupus as compared to standard diagnosis laboratory testing.²⁷ The primary endpoint of the trial was the change in the physicians' estimate of likelihood of SLE before and after testing (12 weeks after enrollment). Physicians estimated the likelihood on a 5-point Likert scale ranging from 0 (very low) to 4 (very high). At baseline, pretest likelihood was similar between the standard diagnosis laboratory testing group and the Avisé Lupus test group and the likelihood of SLE decreased in both groups after testing, but the magnitude of the decrease was greater in the Avisé Lupus test group. The change in likelihood of SLE from randomization to post-test was -0.44 ± 0.10 in the Avisé Lupus test group versus -0.19 ± 0.07 in the standard diagnosis laboratory testing group (p=.027). The corresponding changes from baseline to end of study at week 12 was -0.31 ± 0.10 versus -0.61 ± 0.10 (p=.025), for each group respectively. Study limitations are outlined in Tables 7 and 8.

Table 7. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Follow-Up ^e
Wallace et al (2019) ²⁷			2. In the standard diagnosis laboratory group, physicians were not directed to order any specific laboratory test.	1. Formal diagnosis, or fulfillment of classification of SLE not included	1. Short follow-up did not allow for confirmation of SLE diagnosis or impact on longer term health outcomes

SLE: systemic lupus erythematosus.

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use; 5. Enrolled study populations do not reflect relevant diversity; 6. Other.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest; 5. Other.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported; 7. Other.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 8. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective reporting ^c	Data completeness ^d	Power ^e	Statistical ^f
Wallace et al (2019) ²⁷		1. No blinding was used in the study	2. Between group differences in quality of life measures were not reported		1. Power calculations were not performed	4. Median differences and 95% confidence intervals between treatment groups for outcomes were not reported

SLE: systemic lupus erythematosus.

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias; 5. Other.

^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician; 4. Other.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication; 4. Other.

^d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials); 7. Other.

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference; 4. Other.

^f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated; 5. Other.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

A more accurate and timelier diagnosis of SLE (ie, before multiorgan system involvement) and other CTDs could lead to better patient management (e.g., more appropriate medical treatment). This, in turn, could improve health outcomes (e.g., less joint or organ damage, improved survival).

Section Summary: Systemic Lupus Erythematosus

The diagnostic accuracy of the serum biomarker panel test was primarily evaluated in observational studies in patients with established SLE. The intended use population is patients with signs and/or symptoms suggestive of SLE. Including only patients who meet ACR criteria in studies may overestimate performance characteristics compared to the broader population of those with suggestive symptoms. Several retrospective studies did not include statistical comparison to appropriate comparator methods of diagnosis performed concurrently with the Avise test. One RCT evaluated the influence of test results from Avise and standard diagnosis laboratory testing on rheumatologists' likelihood of diagnosing SLE, which found that physicians were less likely to diagnosis SLE in a patient with a negative Avise test. The short follow-up period of the study limits an assessment on how this information would impact health outcomes. Additionally, the comparator arm in the trial, which was not standardized, may not be reflective of current practice where classification criteria are used widely. Regarding ongoing SLE monitoring/management, the AVISE SLE Monitor provides additional information for the assessment of lupus disease activity, risk for kidney damage (lupus nephritis), and potential improvement in SLE symptoms; however, clinical data evaluating use of the test are lacking.

Connective Tissue Diseases Other Than Systemic Lupus Erythematosus

Clinical Context and Test Purpose

The purpose of serum biomarker panel testing is to provide a diagnostic option that is an alternative to or an improvement on existing tests, such as clinical diagnosis and individual serum biomarker tests, in patients with signs and/or symptoms of CTDs other than SLE.

The following PICO was used to select literature to inform this review.

Populations

The population of interest is individuals with signs and/or symptoms of CTD (other than SLE). Presenting clinical features of CTD are highly variable and can be non-specific, which contributes to the difficulty in diagnosis.

Interventions

The test being considered is serum biomarker panel testing.

Comparators

Comparators of interest include clinical diagnosis and individual serum biomarker tests.

Outcomes

General outcomes of interest are test accuracy, symptoms, and quality of life. Details are described below in Table 9.

Table 9. Outcomes of Interest for Individuals With Signs and/or Symptoms of Connective Tissue Disease (Besides Systemic Lupus Erythematosus)

Outcomes	Details
Test accuracy	Sensitivity and specificity in detecting biomarkers for CTDs other than SLE [FU for several years to assess accuracy of diagnosis]
Symptoms	Dry eyes and mouth, fatigue, cognitive dysfunction, muscle weakness and inflammation [≥ 2 weeks]

Outcomes	Details
Quality of life	Symptom relief [≥ 3 years] Reduction in joint and organ damage [≥ 3 years]

CTD: connective tissue disease; FU: follow-up; SLE: systemic lupus erythematosus.

Study Selection Criteria

Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., ROC, AUROC, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of diagnostic or risk category.
- Studies involving panel testing should report on commercially-marketed tests.

Review of Evidence

As previously discussed, Putterman et al (2014) published data from a large cross-sectional, industry-sponsored study evaluating serum biomarkers for the diagnosis of SLE.²⁰ They analyzed the 10 markers in the Avise Lupus (plus ANA) using a 2-tier testing logic similar to that employed in the commercially available panel. Of the 794 patients in the study, 161 were diagnosed with rheumatic diseases other than SLE.

A total of 140 (46%) patients with SLE, 9 (3%) patients with other diseases, and 1 healthy volunteer tested positive for at least 1 of the 4 tier 1 markers. Patients testing negative for tier 1 tests underwent tier 2 testing and an index score was calculated. A total of 245 of 276 patients with other rheumatic diseases had an index score of less than 0 (ie, not suggestive of SLE). When the results of tier 1 and tier 2 testings were combined, the overall specificity for distinguishing SLE from other diseases was 86% (245/285).

An earlier study by Kalunian et al (2012) reported on the first cohort of 593 individuals included in the Putterman et al (2014) analysis.¹⁷ Out of 593 participants, 178 patients had rheumatic diseases, 210 had SLE, and 205 were healthy volunteers. Authors evaluated the performance of a 7-marker biomarker panel for the diagnosis of SLE; some markers are included in a commercially available panel test. The biomarkers included ANA, anti-dsDNA, antimutated citrullinated vimentin, and the CB-CAPs (EC4d, PC4d, BC4d). In relation to SLE, the combination of anti-dsDNA and the multivariate logistic regression analysis index score yielded 87% specificity against other rheumatic diseases.

Section Summary: Connective Tissue Diseases Other Than Systemic Lupus Erythematosus

All studies found centered around diagnosing SLE with other CTDs as comparators and did not assess the sensitivity of the biomarker tests to detect CTDs other than SLE. For individuals with signs and/or symptoms of CTD (besides SLE) who receive serum biomarker panel testing, more studies are needed.

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to

guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in April 2023 did not identify any ongoing or unpublished trials that would likely influence this review.

References

1. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. *Medicine (Baltimore)*. May 2006; 85(3): 147-156. PMID 16721257
2. J C-V, Chitkara P, Christianakis S, et al. Finding the best approach to autoimmune connective tissue disease diagnosis (Paid supplement supported by Exagen Diagnostics). *Rheumatology News*. 2014;August:1-8.
3. American College of Rheumatology (ACR). 1997 Update of the 1982 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus. n.d.; <https://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20Revised.pdf>. Accessed April 24, 2023.
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. Sep 1997; 40(9): 1725. PMID 9324032
5. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol*. Sep 2019; 71(9): 1400-1412. PMID 31385462
6. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. *Arthritis Rheum*. Sep 1999; 42(9): 1785-96. PMID 10513791
7. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. Aug 2012; 64(8): 2677-86. PMID 22553077
8. Suresh E. Systemic lupus erythematosus: diagnosis for the non-specialist. *Br J Hosp Med (Lond)*. Oct 2007; 68(10): 538-41. PMID 17974296
9. Food and Drug Administration. Guidance for Industry: Systemic Lupus Erythematosus - Developing Medical Products for Treatment. June 2010. <https://www.fda.gov/media/71150/download>. Accessed April 24, 2023.
10. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. *Arthritis Rheum*. Aug 15 2007; 57(6): 972-9. PMID 17665467
11. Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology

- Damage Index (SDI). *Arthritis Care Res (Hoboken)*. Nov 2011; 63 Suppl 11(0 11): S37-46. PMID 22588757
12. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. *Rheumatology (Oxford)*. Jul 2005; 44(7): 902-6. PMID 15814577
 13. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol*. Feb 2002; 29(2): 288-91. PMID 11838846
 14. Bae SC, Koh HK, Chang DK, et al. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. *Lupus*. 2001; 10(6): 405-9. PMID 11434575
 15. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. *Clin Exp Rheumatol*. 1992; 10(5): 541-7. PMID 1458710
 16. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum*. Mar 1996; 39(3): 363-9. PMID 8607884
 17. Kalunian KC, Chatham WW, Massarotti EM, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. *Arthritis Rheum*. Dec 2012; 64(12): 4040-7. PMID 22932861
 18. Liu CC, Kao AH, Hawkins DM, et al. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. *Clin Transl Sci*. Aug 2009; 2(4): 300-8. PMID 20161444
 19. Navratil JS, Manzi S, Kao AH, et al. Platelet C4d is highly specific for systemic lupus erythematosus. *Arthritis Rheum*. Feb 2006; 54(2): 670-4. PMID 16447243
 20. Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. *Lupus Sci Med*. 2014; 1(1): e000056. PMID 25396070
 21. Wallace DJ, Silverman SL, Conklin J, et al. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. *Lupus Sci Med*. 2016; 3(1): e000127. PMID 26870391
 22. Mossell J, Goldman JA, Barken D, et al. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. *Open Rheumatol J*. 2016; 10: 71-80. PMID 27867431
 23. Liang E, Taylor M, McMahon M. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression. *Lupus Sci Med*. 2020; 7(1): e000345. PMID 32231785
 24. O'Malley T, Xie F, Su Y, et al. Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus. *J Manag Care Spec Pharm*. Sep 2022; 28(9): 1021-1032. PMID 35775579
 25. Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. *Arthritis Rheumatol*. Jan 2020; 72(1): 78-88. PMID 31469249
 26. Ramsey-Goldman R, Alexander RV, Conklin J, et al. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. *ACR Open Rheumatol*. Feb 2021; 3(2): 116-123. PMID 33538130
 27. Wallace DJ, Alexander RV, O'Malley T, et al. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. *Lupus Sci Med*. 2019; 6(1): e000349. PMID 31592328

Documentation for Clinical Review

- No records required

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

Type	Code	Description
CPT®	0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity
	0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score
	0446U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity (Code effective 4/1/2024)
	0447U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare (Code effective 4/1/2024)
	81599	Unlisted multianalyte assay with algorithmic analysis
	83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
	84999	Unlisted chemistry procedure
	86038	Antinuclear antibodies (ANA);
	86039	Antinuclear antibodies (ANA); titer
	86146	Beta 2 Glycoprotein I antibody, each
	86147	Cardiolipin (phospholipid) antibody, each Ig class
	86200	Cyclic citrullinated peptide (CCP), antibody
	86225	Deoxyribonucleic acid (DNA) antibody; native or double stranded
	86235	Extractable nuclear antigen, antibody to, any method (e.g., nRNP, SS-A, SS-B, Sm, RNP, Scl70, J01), each antibody
	86376	Microsomal antibodies (e.g., thyroid or liver-kidney), each
	86800	Thyroglobulin antibody
	88184	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker
	88185	Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)
	88187	Flow cytometry, interpretation; 2 to 8 markers
	88188	Flow cytometry, interpretation; 9 to 15 marker
88189	Flow cytometry, interpretation; 16 or more markers	

Type	Code	Description
HCPCS	None	

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
10/31/2014	BCBSA Medical Policy adoption
08/01/2016	Policy revision without position change
09/01/2017	Policy title change from Serum Biomarker Panel Testing for Systemic Lupus Erythematosus Policy revision without position change
05/01/2018	Coding update
08/01/2018	Policy revision without position change
10/01/2018	Coding update
10/01/2018	Coding update
09/01/2019	Policy revision without position change
08/01/2023	Policy reactivated. Previously archived from 07/01/2020 to 07/31/2023.
05/01/2024	Coding update

Definitions of Decision Determinations

Medically Necessary: Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: MedPolicy@blueshieldca.com

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.

Appendix A

POLICY STATEMENT (No changes)	
BEFORE	AFTER
<p>Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases 2.04.123</p> <p>Policy Statement:</p> <ul style="list-style-type: none"> I. Serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic lupus erythematosus and other connective tissue diseases is considered investigational. 	<p>Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases 2.04.123</p> <p>Policy Statement:</p> <ul style="list-style-type: none"> I. Serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic lupus erythematosus and other connective tissue diseases is considered investigational.